Document Type : Original Article

Authors

1 DGP- Deutsche Gesellschaft fuer Pneumologie Aerztekammer Nordrhein

2 Professor of Rheumatology, Rheumatology Research Center, Tehran University of Medical Sciences, Tehran, Iran

3 Rheumatology Research Ctr Shariati Hospital-Tehran Univ Jalal AI-Ahmad Avenue Tehran 14117 IRAN

4 German Registry of Adamantiades-Behçet's Disease, Department of Dermatology, University Medical Center Benjamin Franklin, Free University of Berlin, Germany

10.32592/RR.2024.9.1.47

Abstract

Adamantiades-Behçet’s disease (ABD) is a chronic, recurrent inflammatory disease with an unclear aetiology. Major and minor clinical signs characterize ABD. Major signs generally comprise oral and genital aphthae and skin and eye manifestations. Minor signs include joint, neurological, and gastrointestinal symptoms and vascular involvement. This work aims to compare the prevalence and clinical manifestations of ABD using available study results from Iran and Germany.This report is based on statistical data from Iran and Germany. A long-term study over 35 years from the Rheumatology Research Center, Shariati Hospital, Tehran University of Medical Sciences, and a large German epidemiological study dealing with data from the German Registry for ABD and data on the disease in Europe are the information sources. Additionally, data from recent ABD studies listed in PubMed are used.Although the prevalence of ABD in Iran, with 80 patients per 100,000 inhabitants, is markedly higher than in Germany, with 4.2 patients per 100,000 inhabitants, the male-to-female ratio and age of onset are similar in the two populations. In Iran, the male-to-female ratio is 1.3:1, and the average onset age is 26 ± 11.3 years. In Germany, the male-to-female ratio is 1.4:1, and the average onset age is 27.7 ± 11.6 years. The incidence of the disease is decreasing, both in Iran and other parts of the world.Recurrent oral aphthae were the most common onset manifestation in patients of both Iran (82.7%) and Germany (84.5%), with ocular manifestations more common onset signs in Iran (8.7%) than in Germany (5.1%). Except for recurrent genital ulcers, which were more common in women in both countries, all other clinical signs – except oral aphthae – were more common in male patients in both countries. Minor clinical signs differed.A markedly different prevalence was observed in the study populations of Iran and Germany, with the disease being more common in Iran. However, despite the different origins, demographics and major clinical signs of ABD were similar in both countries. ABD is most frequently detected in young patients.

Keywords

Main Subjects

  1. Zouboulis CC, Kötter I, Djawari D, et al. Epidemiological features of Adamantiades-Behçet's disease in Germany and in Europe. Yonsei Med J. 1997;38(6):411-422. doi:10.3349/ymj.1997.38.6.411
  2. Zouboulis CC. Epidemiology of Adamantiades-Behçet's disease. Ann Med Interne (Paris). 1999;150(6):488-98.
  3. Waßmuth R. Einführung in das HLA-System. Ecomed Medizin, Verlagsgruppe Hüthig Hehle Rehm GmbH; 2005.
  4. Deutsches Register Morbus Adamantiades Behcet e.V. [https://behcet.de ]
  5. Shahram F, Chams-Davatchi S, Chams H. Behçet's Disease, Vol. 1. Tehran Rheumatology Research Center; 2000.
  6. Davatchi F, Chams-Davatchi C, Shams H, Nadji A,Faezi T, Akhlaghi M, et al. Acta Medica Iranica,43(4):233-242; 2005
  7. Davatchi F, Chams-Davatchi C, Shams H, Nadji A, Faezi T, Akhlaghi M. et al. Adult Behcet's disease in Iran: analysis of 6075 patients. Int J Rheum Dis 2016; 19(1):95-103. doi: 10.1111/1756-185x.12691.
  8. Davatchi F, Jamshidi AR, Banihashemi AT, Gholami J, Forouzanfar MH, Moradi M, Akhlaghi M, Khabazi AR, Salari AH, Salessi M, Karimifar M, Essalat-Manesh K, Hadj-Aliloo M, Arabzadeh B, Alipour B, Shahram F, Nadji A. Prevalence of Behçet’s disease in Iran: A WHO-ILAR COPCORD stage I study. APLAR J Rheumatol 2007;10(3): 239-43. https://doi.org/10.1111/j.1479-8077.2007.00295.x
  9. Krause I, Yankevich A, Fraser A, et al. Prevalence and clinical aspects of Behcet's disease in the north of Israel. Clin Rheumatol. 2007;26(4):555-60. doi:10.1007/s10067-006-0349-4
  10. Davatchi F. Epidemiology of Behçet's Disease in Middle East and Asia. In: Oliveiri SC, Cantini F (eds.). 8th International Congress on Behçet’s Disease. International Society of Behçet’s Disease (ISBD). Milano, Italy; 1998.
  11. Altenburg, A., Mahr, A., Maldini, C. et al. Epidemiologie und Klinik des Morbus Adamantiades-Behçet in Deutschland. Ophthalmologe 109, 531–541 (2012). https://doi.org/10.1007/s00347-012-2601-4
  12. Papoutsis NG, Abdel-Naser MB, Altenburg A, Orawa H, Kötter I, Krause L, Pleyer U, Djawari D, Stadler R, Wollina U, Kohl PK, Gollnick HP, Kirch W, Ochsendorf FR, Keitel W, Martus P, Zouboulis CC. Prevalence of Adamantiades-Behçet's disease in Germany and the municipality of Berlin: results of a nationwide survey. Clin Exp Rheumatol. 2006 Sep-Oct;24(5 Suppl 42):S125. Erratum in: Clin Exp Rheumatol. 2007 May-Jun;25(3):507-8. PMID: 17067445.
  13. International Team for the Revision of the International Criteria for Behçet's Disease (ITR-ICBD). The International Criteria for Behçet's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol. 2014;28(3):338-347. doi:10.1111/jdv.12107
  14. Davatchi F, Chams-Davatchi C, Shams H, et al. Behcet's disease: epidemiology, clinical manifestations, and diagnosis. Expert Rev Clin Immunol. 2017;13(1):57-65. doi:10.1080/1744666X.2016.1205486
  15. Barnes CG. Treatment of Behcet's syndrome. Rheumatology (Oxford). 2006;45(3):245-247. doi:10.1093/rheumatology/kei257
  16. Davatchi F. Development of rheumatology in Tehran University of Medical Sciences. Arch Iran Med. 2009;12(6):605-610.
  17. Davatchi F, Shahram F, Chams-Davatchi C, et al. How to deal with Behcet's disease in daily practice. Int J Rheum Dis. 2010;13(2):105-116. doi:10.1111/j.1756-185X.2010.01462.x
  18. Papoutsis NG, Abdel-Naser MB, Altenburg A, et al. Prevalence of Adamantiades-Behçet's disease in Germany and the municipality of Berlin: results of a nationwide survey [published correction appears in Clin Exp Rheumatol. 2007 May-Jun;25(3):507-8]. Clin Exp Rheumatol. 2006;24(5 Suppl 42):S125.
  19. Davatchi F, Jamshidi AR, Banihashemi AT, et al. WHO-ILAR COPCORD Study (Stage 1, Urban Study) in Iran. J Rheumatol. 2008;35(7):1384.
  20. Davatchi F, Shahram F, Chams-Davatchi C, et al. Behcet's disease in Iran: analysis of 6500 cases. Int J Rheum Dis. 2010;13(4):367-373. doi:10.1111/j.1756-185X.2010.01549.x
  21. Davatchi F, Shahram F, Chams-Davatchi C, et al. Behcet's disease: from East to West. Clin Rheumatol. 2010;29(8):823-833. doi:10.1007/s10067-010-1430-6
  22. Zouboulis CC: Morbus Adamantiades-Behçet. Klinische und experimentelle Befunde von 53 Patienten aus dem Raum Freie Universität Berlin; 1995.
  23. Jaber L, Milo G, Halpern GJ, Krause I, Weinberger A. Prevalence of Behçet's disease in an Arab community in Israel. Ann Rheum Dis. 2002;61(4):365-366. doi:10.1136/ard.61.4.365
  24. Chang HK, Kim JU, Cheon KS, Chung HR, Lee KW, Lee IH. HLA-B51 and its allelic types in association with Behçet's disease and recurrent aphthous stomatitis in Korea. Clin Exp Rheumatol. 2001;19(5 Suppl 24):S31-S35.
  25. Ideguchi H, Suda A, Takeno M, Ueda A, Ohno S, Ishigatsubo Y. Characteristics of vascular involvement in Behçet's disease in Japan: a retrospective cohort study. ClinExpRheumatol. 2011;29(4 Suppl 67):S47-S53.
  26. Cho SB, Cho S, Bang D. New insights in the clinical understanding of Behçet's disease. Yonsei Med J. 2012;53(1):35-42. doi:10.3349/ymj.2012.53.1.35
  27. Mohammad A, Mandl T, Sturfelt G, Segelmark M. Incidence, prevalence and clinical characteristics of Behcet's disease in southern Sweden. Rheumatology (Oxford). 2013;52(2):304-310. doi:10.1093/rheumatology/kes249
  28. Ek L, Hedfors E. Behçet's disease: a review and a report of 12 cases from Sweden. Acta Derm Venereol. 1993;73(4):251-254. doi:10.2340/0001555573251254
  29. Vaiopoulos G, Kaklamani VG, Markomichelakis N, Tzonou A, Mavrikakis M, Kaklamanis P. Clinical features of juvenile Adamantiades-Behçet's disease in Greece.  1999;17(2):256-259.
  30. Zouboulis CC, May T. Pathogenesis of Adamantiades-Behçet’s disease. Med Microbiol Immunol 2003; 192:149-155.doi: 10.1007/0-306-48382-3_33
  31. Shahram F, Nadji A, Jamshidi A, Chams H, Chams C, Shafaie N, Akbarian M, Gharibdoost F, Davatchi F. Behcet’s disease in Iran, analysis of 5059 cases. Arch Iranian Med 7: 9–14, 2004.